

# BCCA Protocol Summary for Non-Steroidal Treatment of Prostate Cancer

**Protocol Code:** GUPNSAA  
**Tumour Group:** Genitourinary  
**Contact Physicians:** Dr. Kim Chi  
Dr. T. Pickles

## ELIGIBILITY/TESTS:

Treatment of prostate cancer where the addition of an anti-androgen in addition to medical or surgical orchiectomy is indicated as follows:

1. To block a clinical flare at the initiation of LHRH agonist therapy.
2. Second-line hormonal treatment if the patient has not previously received a non-steroid anti-androgen.
3. **Total androgen blockade** of advanced prostate cancer (approved indication for **bicalutamide** or **flutamide** or **niLUTAmide**)

## TREATMENT:

Drug	Dose	BCCA Administration Guideline
bicalutamide*	50 mg daily	PO*
flutamide	250 mg TID	PO Do LFT's q3 months. Discontinue if diarrhea develops
niLUTAmide	150 mg daily	PO  For patients intolerant to bicalutamide or flutamide

\* bicalutamide is the **preferred anti-androgen** for prostate cancer as per Genitourinary Cancer Management Guidelines (see: [www.bccancer.bc.ca/health-professionals/professional-resources/cancer-management-guidelines/genitourinary/prostate#Indications-for-Antiandrogen-Use](http://www.bccancer.bc.ca/health-professionals/professional-resources/cancer-management-guidelines/genitourinary/prostate#Indications-for-Antiandrogen-Use))

## Duration

Indication (1): Treatment should be continued for 3-4 weeks to block clinical flare.

Indication (2), (3): Discontinue at progression of PSA or clinical symptoms or signs.

**Call Dr. Kim Chi or Dr. Tom Pickles or tumour group delegate at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.**

**Date activated:** N/A

**Date revised:** 01 Jul 2016 (Class II registration deleted, TALLman lettering formatted, hyperlink updated)

**References:**

1. Prostate Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials. *Lancet* 2000; 355:1491-98.
2. Schellhammer PR, Sharifi R, Block NL, et al. Clinical benefits of Bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group. *Urology* 1997; 50(3):330-6.
3. Usami M, Akaza H, Arai Y et al. Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients. *Prostate Cancer Prostatic Diseases* 2007; 10(2):194-201.